Mandate

Vinge has advised Autoliv and Veoneer

Vinge has advised Autoliv, Inc. (“Autoliv”) and Veoneer, Inc. (“Veoneer”) in connection with the spin-off and listing of Veoneer on the New York Stock Exchange and Nasdaq Stockholm. First day of regular trading of Veoneer was July 2, 2018.

On December 12, 2017, Autoliv announced that, following the conclusion of a strategic review by the board of directors, it intended to spin-off its Electronics business segment, creating a new, independent publicly traded company called Veoneer, Inc. To implement the spin-off, Autoliv has transferred the Electronics business to Veoneer and its subsidiaries and has distributed 100% of the outstanding shares of common stock of Veoneer on a pro rata basis to existing holders of common shares of Autoliv, including shares represented by Swedish Depository Receipts (“SDRs”). In connection with the spin-off and the listing of shares of Veoneer common stock on the New York Stock Exchange and Veoneer SDRs on Nasdaq Stockholm, Autoliv and Veoneer have prepared a registration statement as well as a Swedish prospectus. The registration statement became effective and the prospectus was approved and registered on June 8, and the first day of regular way trading of Veoneer was July 2, 2018.

Veoneer is a growing technology company, focused on active safety, ADAS, autonomous driving and automotive safety electronics. Veoneer’s purpose is to create trust in mobility.  In 2017, Veoneer (as the Electronics business segment of Autoliv) had a turnover of $2.3 billion. Veoneer currently has around 7,600 associates out of which roughly half are in RD&E. Veoneer’s customers are nearly all the top automotive manufacturers in the world. The market value of Veoneer, Inc. on the first day of trading was approximately SEK 34 billion.

Vinge’s team primarily consisted of Göran Nyström, Dain Hård Nevonen, Malte Hedlund, Sabina Kihlberg and Stephanie Stiernstedt, as well as Albert Wållgren, Helena Håkansson, Lionardo Ojeda and Sara Osman regarding financing issues.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026